Headline
The latest stories from AHA Today.
The Centers for Medicare & Medicaid Services released updated guidance for states and territories on Medicaid, Children’s Health Insurance Program and Basic Health Program coverage and reimbursement for COVID-19 vaccinations.
The Centers for Disease Control and Prevention released recommendations for the ethical allocation of COVID-19 vaccines, once available to the public.
The AHA, along with the American College of Surgeons, American Society of Anesthesiologists and Association of periOperative Registered Nurses, released Joint Statement: Roadmap for Maintaining Essential Surgery during COVID-19 Pandemic, an update to a previous joint statement most recently…
“[T]his year, we need to show our appreciation to our healthcare heroes and the love we have for our family and friends by wearing a mask and avoiding large family gatherings,” writes Robyn Begley, AHA’s chief nursing officer and CEO of the American Organization for Nursing Leadership, in an op-ed…
The Cybersecurity and Infrastructure Security Agency, Federal Bureau of Investigation, and Department of Health and Human Services said they continue to assess the ransomware threat to the health care sector.
The AHA released a detailed summary of two final rules that would modernize and make important changes to policies governing physician self-referral (Stark law) and federal anti-kickback statute regulations.
The National Institutes of Health has awarded about $45 million to expand the research network for its Rapid Acceleration of Diagnostics Underserved Populations program.
The Department of Health and Human Services seeks information on innovative approaches and best practices developed to promote health care access, quality and value during the COVID-19 pandemic to inform the agency’s priorities and programs.
UnitedHealthcare has delayed from April 1, 2021, until Jan. 1, 2022, its requirement that certain in-network laboratories report their unique laboratory-specific codes along with other information for the overwhelming majority of freestanding and outpatient laboratory testing services.
The Food and Drug Administration authorized administering the monoclonal antibodies casirivimab and imdevimab together to certain COVID-19 outpatients at risk for severe disease.